Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A. and Fenwick, E.L. (2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 14(1), pp. 15-23. (doi: 10.1016/j.jval.2010.10.016)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1016/j.jval.2010.10.016
Abstract
Infliximab represents a cost-effective treatment option well within the National Institute for Health and Clinical Excellence threshold relative to palliative care. In light of equivalent outcomes with other tumor necrosis factor α inhibitors, its position in the treatment pathway is likely to be governed by treatment cos
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Briggs, Professor Andrew |
Authors: | Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A., and Fenwick, E.L. |
Subjects: | R Medicine > R Medicine (General) |
College/School: | College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment |
Journal Name: | Value in Health |
ISSN: | 1098-3015 |
University Staff: Request a correction | Enlighten Editors: Update this record